author-photo

Raymond S. McDermott

Boston Children's Hospital

88

Papers

558

Citations

Citation Trend

Filter By

Papers (56) Sort By

Journal Conference Others

Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol). (NCT01726452).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (11)
LBA5 A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: Overall survival with abiraterone acetate plus prednisone in PEACE-1

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Differential CircRNA Expression Signatures May Serve as Potential Novel Biomarkers in Prostate Cancer

2021 Frontiers in Cell and Developmental Biology
Show All
- Source
- Cite
- Save
Citations (1)
535P Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase (TRK) fusion cancer

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (7)
61MO Biomarker analysis of men with enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC) treated with pembrolizumab (pembro) + enza in KEYNOTE-199

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
SO-27 Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
669P Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
KEYNOTE-199 cohorts 4 and 5: Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC)

2020
Show All
- Source
- Cite
- Save
Citations (1)